source
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
- Sun Pharma’s $12 billion Organon deal signals global push but India still faces R&D hurdlesSun Pharma is close to completing a nearly $12 billion purchase of Organon, which would lift the Indian group into the world’s top‑25 pharmaceutical companies and expand its footprint to about 150…